Prazosin after a cat’s urinary blockage: what the trial found
A 2021 trial did not find fewer repeat blockages with prazosin. Its results help explain why plausible mechanisms and common use need to be tested against meaningful outcomes.
Source-linked MSRA literature interpretation. Independent veterinary review has not been recorded. Review and corrections policy
Original study: 2021. The MSRA article date above is the date of this interpretation.
- Who was studied
- Male cats after a first obstruction; 80 randomized and 65 analyzed in the 2021 trial.
- What was measured
- Repeat obstruction within 30 days: 11/37 with prazosin and 5/28 with placebo.
- What remains uncertain
- P=.27; small analyzed groups and exclusions limit inference. Benefit, equivalence and harm were not established.
This is a research explanation, not an instruction to start or stop medicine. If your cat is struggling to pee or passing little or no urine, contact an emergency clinic. If a prescribed medicine concerns you, speak to the treating vet.
After a cat has been unblocked, owners naturally want to prevent another emergency. A medicine can have a plausible reason for use without having demonstrated that outcome. Prazosin is a useful example.
What the researchers tested
Hanson and colleagues compared seven days of prazosin with placebo after relief of a first urethral obstruction. Eighty male cats were randomized; 65 were analyzed. Investigators and owners were blinded, and follow-up included an owner call.
| Repeat obstruction within 30 days | Result |
|---|---|
| Prazosin | 11 of 37 cats (30%) |
| Placebo | 5 of 28 cats (18%) |
The difference was not statistically significant (P = 0.27). This trial did not demonstrate prevention of repeat blockage. The higher percentage with prazosin also does not prove that it caused reblocking. Hanson et al., 2021.
Limits that matter
Twelve cats were excluded for not receiving the full medication course. Exclusions after randomization and small final groups limit confidence. Cats with radiographically identified bladder stones were ineligible, so the result cannot represent every obstructed cat or treatment regimen.
How it fits with other evidence
A separate 2017 randomized, blinded study involving 47 male cats also did not find a clear difference in repeat obstruction or owner-reported urinary signs with prazosin. Its authors explicitly cautioned that the study was underpowered. That means its size limited its ability to detect a difference; it does not mean the treatments were proved equivalent. Reineke et al., 2017.
The 2025 iCatCare consensus guideline says prazosin is not generally recommended on current evidence, while acknowledging remaining questions about possible subgroups and differences between study protocols.
A 2022 observational survey found a different association with recurrence. Its abstract describes veterinarians recruited by their always/never prescribing practice. It does not establish the explanation that difficult cases were selectively prescribed prazosin; confounding direction remains uncertain until fuller methods are checked. Association does not establish that the drug caused harm. Source 31, original abstract.
What an owner can take to the appointment
Ask: “What is this medicine intended to achieve for my cat, what evidence supports that aim, and what should I monitor?” A clinician may be making a decision about a specific patient that this short review cannot assess.
Also ask for clear return instructions. Repeat obstruction remains an emergency after discharge; a medication schedule should never become a reason to wait when urine output is uncertain. Animal Medical Center.
Why MSRA includes negative results
For this library, a useful paper is one that changes the clarity of a decision. Trials that fail to establish a benefit help identify where a reassuring story has outrun its evidence. We apply the same standard to future MSRA research.
MSRA paper-analysis draft. Sources checked 29 October 2026; not independently veterinary reviewed. This study was conducted by its named investigators, not by MSRA. Dosing instructions have intentionally not been reproduced.
Sources used in this explanation
- [11] Effect of prazosin on feline recurrent urethral obstructionOriginal publication: 2021 · Cats with urethral obstruction
- [12] The effect of prazosin on outcome in feline urethral obstructionOriginal publication: 2017 · Cats with urethral obstruction
- [31] Prazosin administration increases the rate of recurrent urethral obstruction in cats: 388 casesOriginal publication: 2022 · Cats with urethral obstruction
- [41] 2025 iCatCare consensus guidelines on the diagnosis and management of lower urinary tract diseases in catsOriginal publication: 2025 · Clinical consensus guideline (cats)
These links retain the report's reference numbers. The index shows original papers, review limits and related MSRA interpretations.
Found a missing source or an error? Suggest a correction. Keep identifiable veterinary records out of public issues.
Literature interpretation can inform questions for your veterinarian; it does not establish an individual diagnosis or validate an MSRA product.